Oral ivermectin is a systemic antiparasitic medication whose distribution and metabolism depend on pathways such as CYP3A4 and P‑glycoprotein (P‑gp). Because these systems regulate drug transport and clearance, interactions can significantly influence ivermectin exposure, tolerability, and overall safety. This makes understanding interaction risks essential, especially when using Stromectol or generic oral formulations.
Unlike topical ivermectin, which has minimal systemic absorption and virtually no interaction profile, oral ivermectin may be affected by CYP3A4 inhibitors or inducers, P‑gp modulators, other antiparasitic agents, and even alcohol‑related side‑effect overlap. This page provides a complete overview of clinically relevant interaction categories. Explore related sections: Ivermectin oral, Ivermectin oral — precautions, Ivermectin general safety.
Informational sources consistently emphasize that oral ivermectin (3 mg / 6 mg tablets; Stromectol) is significantly more susceptible to clinically relevant drug interactions than its topical counterpart. This difference is driven by systemic absorption, metabolic pathways, and the drug’s physicochemical properties. Expanded overview: Ivermectin oral interactions.
Oral ivermectin distributes through the bloodstream, reaching multiple tissues, including peripheral nervous system structures. Informational frameworks highlight that systemic exposure increases the relevance of interactions affecting CNS penetration, hepatic metabolism, and overall drug clearance. Because ivermectin’s tolerability depends on maintaining predictable systemic levels, any factor that alters absorption or metabolism may influence safety.
Ivermectin is highly lipophilic, allowing it to accumulate in fatty tissues and maintain a prolonged presence in the body. Informational sources note that this property increases sensitivity to metabolic fluctuations, as changes in clearance or distribution may prolong exposure or intensify systemic effects.
Oral ivermectin is metabolized primarily by CYP3A4 and transported by P‑glycoprotein (P‑gp). Informational literature highlights that inhibitors or inducers of these pathways may significantly alter systemic exposure. CYP3A4 inhibitors may increase ivermectin levels, while inducers may reduce antiparasitic efficacy. P‑gp inhibitors may increase CNS penetration, raising the risk of neurological side effects.
Topical ivermectin has minimal systemic absorption, which is why informational sources state that it has no clinically meaningful drug–drug interactions. The interaction profile of oral ivermectin is therefore driven entirely by its systemic exposure and reliance on metabolic and transport pathways.
| Factor | Significance |
|---|---|
| Systemic action | Broader interaction potential due to full‑body distribution |
| High lipophilicity | Prolonged exposure increases sensitivity to metabolic changes |
| CYP3A4 metabolism | Inhibitors/inducers significantly alter systemic levels |
| P‑gp transport | Modulators affect CNS penetration and neurological risk |
| Topical vs oral | Topical has minimal interactions; oral has multiple pathways |
Informational sources consistently emphasize that oral ivermectin (3 mg / 6 mg tablets; Stromectol) is highly sensitive to medications and substances that modulate CYP3A4 activity. Because ivermectin relies heavily on CYP3A4 for metabolism, any inhibition or induction of this enzyme can significantly alter systemic exposure. Expanded PK overview: Ivermectin PK.
CYP3A4 inhibitors slow the metabolism of ivermectin, increasing systemic levels and potentially intensifying adverse effects such as dizziness, fatigue, or rare neurological symptoms. Informational literature highlights several major inhibitor groups:
These interactions are especially relevant in individuals with comorbidities, high parasite burden, or concurrent medications affecting P‑glycoprotein.
CYP3A4 inducers accelerate ivermectin metabolism, reducing systemic exposure and potentially lowering antiparasitic effectiveness. This may be clinically significant in strongyloidiasis, crusted scabies, or other high‑burden infections where adequate systemic levels are essential.
Informational frameworks emphasize that CYP3A4 induction may require alternative strategies or closer monitoring in systemic parasitic infections.
| Agent type | Effect on ivermectin |
|---|---|
| Macrolides | Increase systemic exposure; higher CNS risk |
| Azole antifungals | Strong inhibition; elevated ivermectin levels |
| Antiretrovirals | Potent inhibition; increased adverse‑effect potential |
| Grapefruit | Increases oral bioavailability; raises systemic exposure |
| Rifampicin | Strong induction; reduced antiparasitic activity |
| Carbamazepine | Accelerated metabolism; lower systemic levels |
| Phenytoin | Induces CYP3A4; may compromise therapeutic effect |
Informational sources consistently emphasize that P‑glycoprotein (P‑gp) plays a central role in the safety profile of oral ivermectin (3 mg / 6 mg tablets; Stromectol). As an efflux transporter, P‑gp protects the central nervous system (CNS) by limiting ivermectin penetration across the blood–brain barrier. Any factor that inhibits or alters P‑gp function may significantly increase systemic and neurological exposure. Expanded PK overview is available on Ivermectin PK.
Under normal physiological conditions, P‑gp actively pumps ivermectin molecules out of CNS tissues, preventing accumulation in the brain. Informational frameworks highlight that this mechanism is a key safety barrier, ensuring that ivermectin’s systemic distribution does not translate into excessive CNS exposure. When P‑gp function is impaired—genetically or pharmacologically—this protective barrier weakens.
Informational literature emphasizes that P‑gp inhibitors may significantly increase ivermectin penetration into the CNS. This raises the risk of neurological adverse effects, including dizziness, confusion, impaired coordination, or rare CNS toxicity. These risks are more pronounced in individuals with high systemic exposure (e.g., CYP3A4 inhibition, high‑fat meals, high parasite burden).
Several drug classes are referenced as P‑gp modulators, capable of altering ivermectin’s CNS exposure. These include calcium channel blockers, macrolide antibiotics, immunosuppressants, and certain cardiovascular agents. Informational sources also note that genetic P‑gp deficiencies may increase susceptibility.
| P‑gp modulator | Impact on ivermectin |
|---|---|
| Calcium channel blockers | Increase CNS penetration; higher neurological risk |
| Macrolides | Inhibit P‑gp; elevate systemic and CNS exposure |
| Immunosuppressants | Strong inhibition; significant CNS penetration risk |
| Cardiac agents | Alter efflux transport; may intensify CNS effects |
| Genetic P‑gp variants | Reduced transporter function; increased susceptibility |
Informational sources consistently emphasize that oral ivermectin (3 mg / 6 mg tablets; Stromectol) may exhibit pharmacodynamic interactions when used alongside other antiparasitic agents. These interactions do not typically involve CYP3A4 or P‑gp pathways but instead relate to additive inflammatory responses, overlapping gastrointestinal effects, and differences in systemic vs local activity. Expanded comparisons: Ivermectin vs Albendazole and Ivermectin vs Mebendazole.
Albendazole is a systemic benzimidazole anthelmintic metabolized in the liver. Informational frameworks highlight that combining albendazole with ivermectin may increase gastrointestinal discomfort and inflammatory reactions, especially in high‑burden parasitic infections such as strongyloidiasis. Both drugs rely on hepatic pathways, which may increase systemic load in individuals with liver impairment.
Mebendazole has minimal systemic absorption and acts primarily within the gastrointestinal tract. Informational sources note that when used with ivermectin, mebendazole may contribute to additive GI irritation, but systemic interactions are limited. Ivermectin remains the preferred systemic agent for strongyloidiasis or crusted scabies.
Praziquantel is used for trematodes and cestodes and has a distinct mechanism involving calcium influx in parasites. Informational literature notes that co‑administration with ivermectin may increase fatigue, dizziness, or GI symptoms, but no major metabolic interactions are described. The combination is referenced in some broad‑spectrum antiparasitic protocols.
Informational frameworks emphasize that interactions between ivermectin and other anthelmintics are primarily pharmacodynamic, meaning they relate to combined physiological effects rather than metabolic competition. These interactions are most relevant in high‑burden parasitic infections, where rapid parasite die‑off may trigger stronger inflammatory responses.
| Agent | Interaction |
|---|---|
| Albendazole | Additive GI effects; stronger inflammatory reactions possible |
| Mebendazole | GI irritation; limited systemic overlap |
| Praziquantel | Additive CNS/GI symptoms; minimal metabolic interaction |
| High‑burden infections | Stronger die‑off reactions with combination therapy |
Informational sources consistently emphasize that oral ivermectin (3 mg / 6 mg tablets; Stromectol) may exhibit several clinically relevant interactions with different classes of antibiotics. These interactions vary in mechanism—some are CYP3A4‑related, others pharmacodynamic, and a few involve PK variability that may influence systemic exposure. Expanded comparison: Ivermectin vs Doxycycline.
Macrolide antibiotics—such as clarithromycin and erythromycin—are well‑known CYP3A4 inhibitors. Informational frameworks highlight that co‑administration with ivermectin may increase systemic exposure, raising the likelihood of dizziness, fatigue, or rare neurological symptoms. Macrolides may also inhibit P‑glycoprotein, further increasing CNS penetration.
Tetracyclines, including doxycycline, do not significantly affect CYP3A4 or P‑gp pathways. Informational literature instead highlights pharmacodynamic interactions, such as additive gastrointestinal discomfort or increased inflammatory responses in high‑burden parasitic infections. Doxycycline is sometimes referenced as an adjunct in filarial protocols due to its anti‑Wolbachia activity.
Fluoroquinolones—such as ciprofloxacin or levofloxacin—are not strong CYP3A4 modulators, but informational sources note that they may occasionally influence drug clearance, CNS sensitivity, or QT‑related considerations. These interactions are considered rare but may be relevant in individuals with comorbidities or concurrent CNS‑active medications.
| Antibiotic class | Interaction |
|---|---|
| Macrolides | CYP3A4 inhibition; increased systemic and CNS exposure |
| Tetracyclines | Pharmacodynamic overlap; additive GI effects |
| Fluoroquinolones | Rare PK variability; possible CNS sensitivity |
| High‑burden infections | Stronger inflammatory reactions with combination therapy |
Informational sources consistently emphasize that oral ivermectin (3 mg / 6 mg tablets; Stromectol) may exhibit several clinically relevant overlaps with alcohol, even though no direct metabolic interaction is described. The concern arises from ivermectin’s systemic action, its influence on the central nervous system (CNS), and its reliance on hepatic metabolism. These factors make alcohol a potential amplifier of certain adverse effects. Expanded overview: Ivermectin general safety.
Both alcohol and ivermectin may influence CNS activity, which is why informational frameworks highlight the risk of additive neurological effects. These may include dizziness, reduced coordination, drowsiness, or slowed reaction time. The risk is more pronounced when systemic ivermectin levels are elevated (e.g., CYP3A4 inhibition, high‑fat meals, P‑gp inhibition).
Ivermectin relies on hepatic CYP3A4 pathways, while alcohol places an additional metabolic burden on the liver. Informational sources note that this combination may increase hepatic strain, especially in individuals with pre‑existing liver conditions or those taking other hepatically metabolized drugs.
Informational literature highlights that alcohol may intensify common ivermectin side effects, including nausea, abdominal discomfort, fatigue, and headache. These effects are not caused by a direct interaction but by overlapping physiological pathways.
| Factor | Significance |
|---|---|
| CNS effects | Additive dizziness, sedation, impaired coordination |
| Metabolic load | Increased hepatic strain; relevance in liver impairment |
| Side‑effect amplification | Stronger GI symptoms, fatigue, headache |
| Systemic exposure | Higher risk when CYP3A4 or P‑gp are inhibited |
Informational sources emphasize that oral ivermectin (3 mg / 6 mg tablets; Stromectol) may exhibit unique interaction patterns in the context of parasitic infections. These interactions are not strictly pharmacokinetic; instead, they relate to immune status, parasite burden, and concurrent therapies used in severe or systemic infestations. Expanded pages: Ivermectin for strongyloides and Ivermectin for scabies.
Strongyloides stercoralis is associated with the risk of hyperinfection syndrome, especially in individuals receiving immunosuppressive therapy. Informational frameworks highlight that corticosteroids, cytotoxic agents, and biologics may accelerate autoinfection, increasing parasite replication and systemic spread. When ivermectin is administered in this context, interactions are primarily pathophysiological: immunosuppression increases parasite load, which in turn increases the likelihood of Mazzotti‑type inflammatory reactions during treatment.
Crusted scabies is characterized by extremely high mite density and thick hyperkeratotic crusts. Informational sources note that patients often receive anti‑inflammatory or immunomodulating medications, which may alter the course of infestation. Co‑administration of systemic corticosteroids may temporarily reduce inflammation but can also increase mite proliferation, making ivermectin therapy more complex. During treatment, anti‑inflammatory drugs may mask early inflammatory reactions, delaying recognition of Mazzotti‑type responses.
| Condition | Interaction |
|---|---|
| Strongyloidiasis | Immunosuppressants increase hyperinfection risk; stronger die‑off reactions |
| Crusted scabies | Anti‑inflammatory drugs may mask reactions; high parasite load intensifies responses |
| High‑burden infestations | Stronger inflammatory responses during systemic therapy |
Informational sources emphasize that oral ivermectin (3 mg / 6 mg tablets; Stromectol) shares the same active ingredient across strengths, but dosage configuration can influence pharmacokinetics (PK) and, indirectly, the risk of drug interactions. Higher total systemic exposure—whether achieved through more tablets or higher‑strength tablets—may amplify the impact of CYP3A4 and P‑glycoprotein modulation. Expanded dosage pages: Ivermectin 3 mg and Ivermectin 6 mg.
3 mg tablets offer finer titration, allowing more precise weight‑based dosing and incremental adjustments in patients with comorbidities or polypharmacy. This can be relevant when trying to limit peak exposure in the presence of CYP3A4 inhibitors or P‑gp modulators. 6 mg tablets simplify administration in higher total doses, but the resulting larger per‑dose systemic load may increase susceptibility to interaction‑driven changes in exposure.
In individuals with high body weight, informational frameworks note that larger total doses are often referenced to achieve adequate systemic levels. This frequently leads to multi‑tablet regimens (often using 6 mg tablets), increasing the absolute exposure subject to CYP3A4 and P‑gp modulation. Because ivermectin is lipophilic, high body mass may also influence distribution volume and persistence, making interaction effects more variable.
| Dosage factor | Interaction risk |
|---|---|
| 3 mg tablets | Allows finer dose reduction when CYP3A4/P‑gp inhibitors are present |
| 6 mg tablets | Higher per‑dose exposure; interaction effects may be more pronounced |
| High body weight | Requires higher total doses; greater absolute impact of PK modulators |
| Cumulative dose | Higher cumulative exposure increases sensitivity to CYP3A4 and P‑gp changes |
Informational sources consistently emphasize that oral and topical ivermectin differ fundamentally in their interaction profiles due to differences in systemic exposure, metabolic pathways, and absorption characteristics. These distinctions determine when each formulation is referenced and how interaction‑related risks are evaluated. Expanded comparison: Ivermectin oral vs topical.
Topical ivermectin (1% cream, lotions, gels) demonstrates very low systemic absorption, which is why informational frameworks consistently state that it has no clinically meaningful drug–drug interactions. Its action remains localized to the skin, making it suitable for rosacea, Demodex‑related inflammation, and mild scabies. Because systemic exposure is negligible, CYP3A4 and P‑glycoprotein pathways are not involved.
Oral ivermectin (3 mg / 6 mg tablets; Stromectol) undergoes systemic distribution, making it susceptible to interactions involving CYP3A4 metabolism and P‑glycoprotein transport. CYP3A4 inhibitors (macrolides, azoles, antiretrovirals, grapefruit) may increase systemic exposure, while inducers (rifampicin, carbamazepine, phenytoin) may reduce antiparasitic efficacy. P‑gp inhibitors may increase CNS penetration, raising neurological risk.
Informational sources describe topical ivermectin as preferable when avoiding systemic interactions is a priority. This includes dermatologic conditions such as rosacea, Demodex overgrowth, and mild or localized scabies. Topical therapy is also referenced for individuals with polypharmacy, hepatic impairment, or sensitivity to CNS‑active agents.
| Factor | Interaction relevance |
|---|---|
| Systemic exposure | Oral: high → multiple interactions; Topical: minimal → negligible interactions |
| CYP3A4 involvement | Oral: metabolized by CYP3A4; Topical: no metabolic interaction |
| P‑gp relevance | Oral: CNS protection depends on P‑gp; Topical: not applicable |
| Preferred scenarios | Oral: high‑burden infections; Topical: dermatologic conditions |
Informational sources emphasize that commercial differences between generic oral ivermectin and Stromectol can indirectly influence the interaction profile of the drug. While both contain the same active ingredient, variations in excipients, manufacturing standards, and tablet dissolution characteristics may affect systemic exposure and therefore the magnitude of interactions involving CYP3A4 and P‑glycoprotein pathways. Expanded references: Stromectol and Stromectol price.
Generic ivermectin is produced by multiple manufacturers, resulting in variability in excipients, hardness, and dissolution rates. Informational frameworks note that such variability may influence absorption speed and peak concentration—factors relevant when CYP3A4 inhibitors or P‑gp modulators are present. Stromectol, the branded formulation, is referenced for greater batch‑to‑batch consistency, which may provide more predictable PK behavior in interaction‑sensitive scenarios.
Excipients may influence tablet disintegration, absorption rate, and tolerability. Informational sources highlight that certain excipients may alter gastric emptying or interact with other orally administered drugs, indirectly affecting ivermectin’s systemic exposure. These differences are more relevant in polypharmacy or in patients with GI sensitivity.
Because ivermectin’s interaction risks depend on systemic exposure, any commercial factor that alters absorption or dissolution may influence the magnitude of CYP3A4‑ or P‑gp‑mediated interactions. Stromectol’s consistent PK profile may reduce variability, while generics may produce higher or lower peaks, affecting susceptibility to inhibitors or inducers.
| Commercial factor | Interaction relevance |
|---|---|
| Generic variability | May alter absorption; affects CYP3A4/P‑gp interaction magnitude |
| Stromectol consistency | Predictable PK; more stable interaction profile |
| Excipient differences | Influence dissolution and tolerability; relevant in polypharmacy |
| PK variability | Higher peaks increase CNS and systemic interaction risks |